Evaluation of dAroLutamide Addition to anDrogen Deprivation Therapy and radIatioN Therapy in Newly Diagnosed Prostate Cancer With Pelvic Lymph Nodes Metastases

Overview

Prospective, multicenter, comparative, randomized placebo-controlled Phase III trial - patients with hormone-naïve prostate cancer and pelvic lymph nodes metastases

Detailed description

Standard of care for patients with prostate cancer (PC) with pelvic lymph nodes metastases is radiotherapy (RT) with long-term androgen deprivation therapy (ADT). . Darolutamide improves survival in men with castration-refractory non metastatic prostate cancer. We hypothesize that adding Darolutamide to ADT and RT could improve FFS for these high-risk patients.

Interventions

• Drug Darolutamide 300 mg
  Darolutamide regimen will be of 2 tablets of 300 mg orally twice daily for 24 months.
• Drug Placebo of Darolutamide
  Placebo of Darolutamide regimen will be of 2 tablets of 300 mg orally twice daily for 24 months.

Primary outcome measures

• Failure-free survival FFS [Time frame: 3 years]

Secondary outcome measures (10)

• Metastasis-free survival rates [Time frame: 3 years]
• Progression free survival rate [Time frame: 3 years]
• PSA response levels [Time frame: 3 years]
• Overall survival rates [Time frame: 3 years]
• Cancer-specific survival rates [Time frame: 3 years]
• Time to pain progression [Time frame: 3 years]
• Toxicities [Time frame: 3 years]
• Quality of life of the patient [Time frame: 3 years]
• Quality of life of the patient [Time frame: 3 years]
• Quality of life of the participants [Time frame: 3 years]

Eligibility criteria

Inclusion criteria

• . Newly diagnosed, histologically confirmed prostate adenocarcinoma
• ≥ 18 years old.
• Initial staging with Pelvic MRI, body CT-scan/bone scan or Choline or PSMA PET-CT
• Any T stage
• N stage: N1 - Pelvis lymph nodes metastases (upper limit defined as the L4/L5 interspace).
• Intention to treat with long-term androgen deprivation therapy (24 months).
• Hormonal therapy with LH-RH agonist or antagonist is allowed up to 3months prior to randomization.
• Able to receive protocol therapy and have life expectancy of at least 36 months, ECOG Performance Status (PS) 0-2.
• . Blood counts at screening: hemoglobin ≥ 9.0 g/dl, absolute neutrophil count ≥ 1500/μl (1.5x109/l), platelet count ≥ 100,000/μl (100x109/l ) (patient must not have received any growth factor or blood transfusion within 7 days of the hematology laboratory obtained at screening).
• Screening values of serum alanine aminotransferase (ALT) and/or aspartate transaminase (AST) < 2.5 x upper limit of normal (ULN), total bilirubin < 1.5 x ULN (except patients with a diagnosis of Gilbert's disease), creatinine < 2.0 x ULN.
• Sexually active patients, unless surgically sterile, must agree to use condoms as an effective barrier method during the study treatment and for 3 months after the end of the study treatment.
• Written informed consent.
• Willing and expected to comply with follow-up schedule.
• Affiliated to the social security system.
• Use of 5-α reductase inhibitors (finasteride, dutasteride) is allowed

Exclusion criteria

• Lymph nodes metastases outside of the pelvis
• Bone or visceral metastases
• Prior systemic therapy for locally-advanced prostate cancer except for LH-RH agonist or antagonist up to 3 months before randomization
• Prior treatment with:

• Second generation AR inhibitors such as enzalutamide, apalutamide (ARN-509), darolutamide (ODM-201) other investigational AR inhibitors
• CYP17 enzyme inhibitor such as abiraterone acetate, TAK-700 or
• Oral ketoconazole
• Use of estrogens, or AR inhibitors (bicalutamide, flutamide, nilutamide, cyproterone acetate)
• Use of systemic corticosteroid with dose greater than the equivalent 10 mg of prednisone/day within 28 days before randomization.
• Patients with QTor QTc interval > 450 ms on the ECG
• Initiation of treatment with bisphosphonate or denosumab within 12 weeks before randomization. Patients receiving bone loss prevention treatment on a stable dose of e.g. bisphosphonate or denosumab for at least 28 days before randomization can continue the treatment during the study.
• Known hypersensitivity to the study treatment (RT, ADT, darolutamide/placebo) or any of its ingredients.
• Major surgery within 28 days before randomization.
• Any of the following within 6 months before randomization: stroke, myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft; congestive heart failure New York Heart Association (NYHA) Class III or IV or arterial thromboembolic event.
• Uncontrolled hypertension as indicated by a resting systolic BP > 160 mmHg or diastolic BP > 100 mmHg at screening. Patients may be re-screened after adjustments of anti- hypertensive medications.
• Prior malignancy. Adequately treated basal cell or squamous cell carcinoma of skin or superficial bladder cancer that has not spread behind the connective tissue layer (i.e. pTis, pTa, and pT1) is allowed, as well as any other cancer for which chemotherapy has been completed > 5 years ago and from which the patient has been disease-free.
• Gastrointestinal disorder or procedure which expects to interfere significantly with absorption of study treatment.
• Active viral hepatitis, active human immunodeficiency virus (HIV) or chronic liver disease.
• Participation in another interventional clinical trial and any concurrent treatment with any investigational drug
• Any condition that in the opinion of the investigator would impair the patients' ability to comply with the study procedures.
• Unable to swallow study medications and comply with study requirements.
• Galactose intolerance, the Lapp lactase deficiency or glucose galactose-malabsorption
• History of bilateral hip replacements making IMRT impossible
• Contra-indications for the administration of any of the study treatments (RT, ADT, Darolutamide/placebo) or any of its ingredients.
• Patient under guardianship, administrative tutorship and incapable to give informed consent

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

Randomized

Model

Parallel assignment

Masking

Triple blind

Primary purpose

Treatment

Study locations

France · 1 center

• Pôle Santé Léonard de Vinci — Chambray-lès-Tours

Identifiers

NCT: NCT05116475 · ALADDIN

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗